The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal market, unlocking a $2.5 billion market opportunity. This strategic move positions Globus to further add to ...

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results, is ...

Following strong financial results revealed last month, US-headquartered Globus Medical has agreed to acquire spinal cord stimulation (SCS) company Nevro for $250m to reinforce its position in the ...

Nevro Corp has been recognized for its differentiated high-frequency SCS offerings and solid sales base. However, the company has faced challenges in recent years, struggling with market share and ...

Shares of Nevro Corp. (NYSE:NVRO – Get Free Report) have earned a consensus rating of “Reduce” from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. Two investment ...

StockNews.com assumed coverage on shares of Nevro (NYSE:NVRO – Free Report) in a report issued on Sunday. The brokerage issued a hold rating on the medical equipment provider’s stock. Other equities ...

In addition to the U.S. market release, Nevro introduced the HFX iQ SCS system in select European countries in January 2025 following the receipt of CE Mark Certification in November 2024.

During the fourth quarter of 2024, Nevro made significant advancements in its product offerings and market expansion. The company launched the full market release of HFX iQ with HFX AdaptivAI, a ...

Nevro Corp. engages in the development of medical ... It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of ...